boldenone acetate gainsborough


Confirmed or suspected breast cancer; progestagenzavisimye diagnosed or suspected neoplasms; Confirmed or suspected estrogen-dependent tumors, including cancer of the endometrium; vaginal bleeding of unknown etiology; Untreated endometrial hyperplasia; thromboembolic disease present or in history (eg deep vein thrombosis, pulmonary embolism); Arterial thrombosis present or in history (eg myocardial infarction); thrombophilic disorders (such as protein C deficiency, S or antithrombin protein); acute or chronic liver disease at present or in history (up to normalization of laboratory parameters);porphyria; Hypersensitivity to the drug; galactose intolerance, lactase deficiency, malabsorption syndrome, glucose-galactose. Admission Fboldenone acetate gainsborough should be discontinued in detecting contraindications and / or under the following conditions: jaundice and / or liver dysfunction; a significant increase in blood pressure; appearance on  migraine attack.


Precautions: uterine leiomyoma, endometriosis; risk factors for thromboembolic events, including angina pectoris, prolonged immobilization, severe obesity (body mass index over 30 kg / m 2 ); the presence of risk factors for the occurrence of estrogen-dependent tumors (e.g., first degree hereditary breast cancer); arterial hypertension; liver disease (eg liver adenoma); diabetes is the presence of vascular complications, and in the case of absence; cholelithiasis; migraine or severe headache; systemic lupus erythematosus; endometrial hyperplasia in history; epilepsy; bronchial asthma; otosclerosis.

Pregnancy and lactation: The drug is contraindicated during pregnancy and lactation. In the event of pregnancy during treatment with the drug boldenone acetate gainsborough, therapy should be discontinued immediately.


Dosage and administration:

the drug is taken orally 1 tablet per day. During the first 14 days of a 28 day cycle taken daily for 1 tablet of white color (from half of the package arrow labeled number “1”), containing 1 mg of estradiol, and the remaining 14 days – daily 1 sulfur tablet (from half of the package with an arrow marked with the number “2”), containing 1 mg estradiol and 10 mg dydrogesterone. Treatment should be continued without interruption, immediately after the 28-day cycle, you should start the next treatment cycle.


Side effects: headache, migraine; nausea, abdominal pain, bloating; Voltage / breast tenderness, metrorrhagia, spotting from the vagina, pain in the abdomen;cramps in the muscles of the lower extremities; asthenia; increase or reduction of body weight.

A list of all side effects presented in the instructions for use.



theoretically, in the case of overdose can cause symptoms such as nausea, vomiting, drowsiness, dizziness. Treatment – symptomatic.


Interaction with other drugs: estrogenic and gestagenic action boldenone acetate gainsborough be reduced in the following cases: concomitant use with drugs-inducers of microsomal liver enzymes: anticonvulsant (phenobarbital, carbamazepine, phenytoin) and anti-microbial drugs (rifampicin, rifabutin, nevirapine, efavirenz); herbal preparations containing St. John’s wort; ritonavir, and nelfinavir. Estrogens may affect the metabolism of other drugs: cyclosporine and tacrolimus, theophylline and fentanyl.


Special instructions:

The drug is prescribed only when boldenone acetate gainsborough symptoms that adversely affect quality of life. Therapy should be continued for as long as the benefits of taking the drug outweigh the risks of side effects. The experience of the drug in women older than 65 years is limited.